In vitro assessment for antimicrobial activity against respiratory viruses
Ended Awarded Last action
- Contract number
- 75N93023F00001
- Awardee
-
Utah State University UEI SPE2YDWHDYU4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $456,000
Award facts
- Contract value 53% obligated
-
- $456,000.00 Current, with exercised options
- $864,150.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Logan, UT 84322, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$5,572 | |
| Exercise an Option | $5,572 | |
| Original award | $456,000 |
About this award
Utah State University received a $864,150 firm fixed-price delivery order from the National Institute of Allergy and Infectious Diseases (NIAID) for in vitro assessment of antimicrobial activity against respiratory viruses under the FY26 Urgent Deployment Operations initiative. This delivery order is issued under the parent In Vitro Assessments of Antimicrobial Activity (IVAAA) indefinite delivery vehicle, which represents a significant component of NIAID's $146.3M single-award contract through July 2031 for pre-clinical models of infectious diseases. Work will be performed in Logan, Utah, with an ultimate completion date of June 14, 2024. No set-aside designation was used for this award.
This delivery order supports NIAID's critical mission in biodefense and public health preparedness by advancing testing capabilities for countermeasures including vaccines, therapeutics, and diagnostics against respiratory viral agents with pandemic potential. Utah State University's selection reflects its substantial capacity in specialized viral screening and infectious disease research, demonstrated through previous contract awards exceeding $653,000 from NIAID for comprehensive viral screening panels and support from over $2.8M in NIAID grants for pre-clinical infectious disease models and vaccine development research. The firm fixed-price structure and no set-aside designation underscore USU's status as a qualified institutional contractor capable of managing complex federal research initiatives supporting national health security objectives.
Quick answers
Who was awarded contract 75N93023F00001?
75N93023F00001 was awarded to Utah State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 15, 2023.
How much is contract 75N93023F00001 worth?
The government has obligated $456,000 on 75N93023F00001. Its potential value, with all options, is $864,150.
Is contract 75N93023F00001 an order under another contract?
Yes. 75N93023F00001 is a delivery order under 75N93019D00021, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93023F00001 competed?
The extent of competition for 75N93023F00001 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award